CDNA
$78.87
Caredx
($4.50)
(5.40%)
CDNA
Earnings Whisper ®
N/A
1st Quarter March 2021
Consensus:  ($0.14)
Revenue:  $61.05 Mil
Wednesday
May 26
4:00 PM ET
Score
Grade
Tweet Share Watch
Tweet Share Watch
Guidance announcement made Wednesday, February 24, 2021
Latest EPS
Wednesday, February 24, 2021

What do you expect when CDNA reports earnings?
Beat
Meet
Miss

Where is CDNA's stock price going from here?
Up
Flat
Down
Stock chart of CDNA
Analysts
Summary of analysts' recommendations for CDNA
Score
Grade
Pivots
Resistance
$91.46
$89.76
$86.57

$84.87

Support
$81.68
$79.98
$76.79
Tweet
Growth
Description
CareDx, Inc. is a commercial stage company. It develops, markets, and delivers a diagnostic surveillance solution for heart transplant recipients. The Company provides AlloMap, a noninvasive blood test used to aid in the identification of heart transplant recipients. It is also pursuing other areas of transplant surveillance, such as the use of cell-free DNA (cfDNA) as a biomarker for rejection. CareDx, Inc. is based in Brisbane, California.
Peers
Myriad GeneticsQuidelMeridian BioscienceSurModics